Briacell Therap (BCTX) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp. (NASDAQ: BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for cancer. The company focuses primarily on treatments for advanced breast cancer, with an emphasis on stimulating a patient’s immune system to recognize and attack tumor cells.

BriaCell’s lead product candidate is Bria-IMT, an immunotherapy derived from a breast cancer cell line and designed to activate cancer-fighting immune responses. The company has evaluated Bria-IMT in clinical studies for metastatic breast cancer, including in combination with immune checkpoint inhibitors. BriaCell is also developing Bria-OTS, an off-the-shelf immunotherapy platform intended to provide broader patient compatibility while supporting personalized cancer treatment approaches.

BriaCell Therapeutics is headquartered in Vancouver, British Columbia, and conducts its research and clinical development activities in North America. The company’s programs remain investigational and are subject to clinical and regulatory review. William Williams has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $3.91 to $4.00
• 50-Day Range: $3.36 to $4.32
• 52-Week Range: $2.60 to $14.68
• Volume: 23,266 shs
• Average Volume: 144,053 shs
• Market Capitalization: $34.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Briacell Therap Stock Analysis - MarketRank™

Briacell Therap scored higher than 15% of companies evaluated by MarketBeat, and ranked 867th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Briacell Therap has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Briacell Therap has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Briacell Therap is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Briacell Therap is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Briacell Therap has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.02% of the float of Briacell Therap has been sold short.

Short Interest Ratio / Days to Cover

Briacell Therap has a short interest ratio ("days to cover") of 3.89, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Briacell Therap has recently decreased by 1.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Briacell Therap does not currently pay a dividend.

Dividend Growth

Briacell Therap does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Briacell Therap has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Briacell Therap this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Briacell Therap to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Briacell Therap insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.74% of the stock of Briacell Therap is held by insiders.

Percentage Held by Institutions

15.42% of the stock of Briacell Therap is held by institutions.

Company Calendar

• Last Earnings: 6/09/2026
• Today: 10/10/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCTX
• CIK: 1610820
• Web: www.briacell.com
• Phone: (604) 921-1810
• Fax: 604-921-1898
• Employees: 4
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($7.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -153.53%
• Return on Assets: -129.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.07
• Quick Ratio: 7.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.20 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 8,700,000
• Free Float: 8,636,000
• Market Cap: $34.02 million
• Optionable: No Data
• Beta: 1.21